Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 2/2016

01-06-2016 | Original Research

Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States

Authors: Kimberly A. Lowe, Mark D. Danese, Michelle L. Gleeson, Wendy J. Langeberg, Juan Ke, Michael A. Kelsh

Published in: Journal of Gastrointestinal Cancer | Issue 2/2016

Login to get access

Abstract

Purpose

Comorbidities are known to impact quality of life, treatment choices, and survival. Our objectives were to characterize comorbid conditions in a cohort of elderly gastric cancer patients and to determine if there is variability in the prevalence or incidence of the comorbid conditions across racial/ethnic groups.

Methods

A total of 12,612 individuals, ≥66 years of age, diagnosed with gastric cancer between 2000 and 2007, and an equal number of gender- and region-matched cancer-free individuals, were identified using the National Cancer Institute’s Surveillance, Epidemiology, and End Results registry linked to Medicare claims in the United States. The prevalence (%) in the year before diagnosis and the 12-month incidence rates after diagnosis were estimated for 32 chronic and ten acute comorbid conditions for the entire cohort and by race/ethnicity (Asian, Black, Hispanic, White, and other) and Asian subgroups (e.g., Chinese, Filipino, Japanese, Pacific Islander).

Results

White and Black cases exhibited the highest prevalence of most comorbid conditions. Asian and Pacific Islander cases exhibited the lowest. There was substantial variability in the 12-month incidence of the comorbidities across the racial/ethnic groups. Electrolyte disorder was the most common incident condition among Whites and Blacks. With the exception of Whites, anemia was the most common incident condition in all racial and ethnic groups 180 days following chemotherapy.

Conclusions

There is variability in the prevalence and incidence in comorbidities across racial/ethnic groups.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
2.
go back to reference Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
5.
go back to reference Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? What are the suggestions? Crit Rev Oncol Hematol. 2001;40(1):77–94.CrossRefPubMed Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? What are the suggestions? Crit Rev Oncol Hematol. 2001;40(1):77–94.CrossRefPubMed
6.
go back to reference Gill S, Shah A, Le N, et al. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J Clin Oncol. 2003;21(11):2070–6. Gill S, Shah A, Le N, et al. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J Clin Oncol. 2003;21(11):2070–6.
8.
go back to reference van Gestel YR, Lemmens VE, de Hingh IH, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol. 2013;20(2):371–80. van Gestel YR, Lemmens VE, de Hingh IH, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol. 2013;20(2):371–80.
9.
go back to reference Gonzalez EC, Ferrante JM, Van Durme DJ, et al. Comorbid illness and the early detection of cancer. South Med J. 2001;94(9):913–20. Gonzalez EC, Ferrante JM, Van Durme DJ, et al. Comorbid illness and the early detection of cancer. South Med J. 2001;94(9):913–20.
10.
go back to reference Iversen LH, Nørgaard M, Jacobsen J, et al. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006—a population-based cohort study. Dis Colon Rectum. 2009;52(1):71–8. Iversen LH, Nørgaard M, Jacobsen J, et al. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006—a population-based cohort study. Dis Colon Rectum. 2009;52(1):71–8.
11.
go back to reference Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55(3):231–40. Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55(3):231–40.
12.
go back to reference Lemmens VE, Janssen-Heijnen ML, Verheij CD, et al. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005;92(5):615–23. Lemmens VE, Janssen-Heijnen ML, Verheij CD, et al. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005;92(5):615–23.
13.
go back to reference Coebergh JW, Janssen-Heijnen ML, Post PN, et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol. 1999;52(12):1131–6. Coebergh JW, Janssen-Heijnen ML, Post PN, et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol. 1999;52(12):1131–6.
14.
go back to reference Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.
17.
go back to reference Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8):3–18. IV. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8):3–18. IV.
18.
go back to reference Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.
19.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRefPubMed
20.
go back to reference Romano PS, Roos LL, Luft HS, et al. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol. 1994;47(3):249–60. Romano PS, Roos LL, Luft HS, et al. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol. 1994;47(3):249–60.
21.
go back to reference Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2191–7. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2191–7.
22.
go back to reference Hilbe JM. Negative binomial regression. New York: Cambridge University Press; 2007.CrossRef Hilbe JM. Negative binomial regression. New York: Cambridge University Press; 2007.CrossRef
23.
go back to reference McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall; 1989.CrossRef McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall; 1989.CrossRef
24.
go back to reference Aschengrau A, Seage GR. Essentials of epidemiology in public health. Boston: Jones and Bartlett Publishers; 2003. Aschengrau A, Seage GR. Essentials of epidemiology in public health. Boston: Jones and Bartlett Publishers; 2003.
25.
go back to reference O’Malley, CD Chia V, Lindquist K, et al. Detection bias and the high incidence of diabetes after breast cancer diagnosis. Ann Epidemiol. 2010;20:691–2. O’Malley, CD Chia V, Lindquist K, et al. Detection bias and the high incidence of diabetes after breast cancer diagnosis. Ann Epidemiol. 2010;20:691–2.
26.
go back to reference Liedman B. Symptoms after total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients—is reconstruction with a reservoir worthwhile? Nutrition. 1999;15(9):677–82.CrossRefPubMed Liedman B. Symptoms after total gastrectomy on food intake, body composition, bone metabolism, and quality of life in gastric cancer patients—is reconstruction with a reservoir worthwhile? Nutrition. 1999;15(9):677–82.CrossRefPubMed
27.
go back to reference Shils ME. Nutritional problems associated with gastrointestinal and genitourinary cancer. Cancer Res. 1977;37(7 Pt 2):2366–72.PubMed Shils ME. Nutritional problems associated with gastrointestinal and genitourinary cancer. Cancer Res. 1977;37(7 Pt 2):2366–72.PubMed
28.
go back to reference Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer. 2002;95(10):2096–102.CrossRefPubMed Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer. 2002;95(10):2096–102.CrossRefPubMed
29.
go back to reference Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol. 2004;99(4):582–8.CrossRefPubMed Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol. 2004;99(4):582–8.CrossRefPubMed
30.
go back to reference Lau M, Le A, El-Serag HB. Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol. 2006;101(11):2485–92.CrossRefPubMed Lau M, Le A, El-Serag HB. Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol. 2006;101(11):2485–92.CrossRefPubMed
31.
go back to reference Wu X, Chen VW, Ruiz B, et al. Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences. Cancer. 2006;106(3):683–92. Wu X, Chen VW, Ruiz B, et al. Incidence of esophageal and gastric carcinomas among American Asians/Pacific Islanders, whites, and blacks: subsite and histology differences. Cancer. 2006;106(3):683–92.
33.
go back to reference Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27–39. Dicken BJ, Bigam DL, Cass C, et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241(1):27–39.
34.
go back to reference Kim DY, Joo JK, Ryu SY, et al. Clinicopathological characteristics of patients with proximal third gastric carcinoma. Acta Chir Belg. 2004;104(6):677–82. Kim DY, Joo JK, Ryu SY, et al. Clinicopathological characteristics of patients with proximal third gastric carcinoma. Acta Chir Belg. 2004;104(6):677–82.
35.
go back to reference NCCN. NCCN Clinical Practice Guidelines in Oncology: gastric cancer (including cancer in the proximal 5cm of the stomach). 2013. NCCN. NCCN Clinical Practice Guidelines in Oncology: gastric cancer (including cancer in the proximal 5cm of the stomach). 2013.
36.
go back to reference NCCN. NCCN Clinical Practice Guidelines in Oncology: esophageal and esophagastric junction cancer (exluding cancer in the proximal 5cm of the stomach). 2013. NCCN. NCCN Clinical Practice Guidelines in Oncology: esophageal and esophagastric junction cancer (exluding cancer in the proximal 5cm of the stomach). 2013.
37.
go back to reference McCulloch P, Ward J, Tekkis PP, et al. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327(7425):1192–7. McCulloch P, Ward J, Tekkis PP, et al. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327(7425):1192–7.
38.
go back to reference Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007;43(15):2179–93. Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007;43(15):2179–93.
39.
go back to reference Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150(12):849–57. W152. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150(12):849–57. W152.
40.
go back to reference Chia VM, O'Malley CD, Danese MD, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129(2):346–52. Chia VM, O'Malley CD, Danese MD, et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol. 2013;129(2):346–52.
41.
go back to reference Chia VM, Page JH, Rodriguez R, et al. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Breast Cancer Res Treat. 2013;138(2):621–31. Chia VM, Page JH, Rodriguez R, et al. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Breast Cancer Res Treat. 2013;138(2):621–31.
42.
go back to reference Danese MD, Gleeson ML, Langeberg WJ, et al. Prevalence and incidence of comorbidities associated with stomach cancer. San Francisco, CA: ASCO - GI; 2014. January 2014. Danese MD, Gleeson ML, Langeberg WJ, et al. Prevalence and incidence of comorbidities associated with stomach cancer. San Francisco, CA: ASCO - GI; 2014. January 2014.
43.
go back to reference Danese MD, O'Malley C, Lindquist K, et al. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol. 2012;23(7):1756–65. Danese MD, O'Malley C, Lindquist K, et al. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol. 2012;23(7):1756–65.
Metadata
Title
Racial and Ethnic Variability in the Prevalence and Incidence of Comorbidities Associated with Gastric Cancer in the United States
Authors
Kimberly A. Lowe
Mark D. Danese
Michelle L. Gleeson
Wendy J. Langeberg
Juan Ke
Michael A. Kelsh
Publication date
01-06-2016
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 2/2016
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9809-5

Other articles of this Issue 2/2016

Journal of Gastrointestinal Cancer 2/2016 Go to the issue

Letter to the Editor

Pancreatic Cystic Mass